INTRODUCTION

Bladder cancer is the second most common malignancy of the genitourinary tract and is ranked fourth. Urothelial carcinoma of the bladder is the most common histologic type of bladder cancer, which of them initially diagnosed as non-muscle-invasive bladder cancer, which is confined to either the mucosa (pT1a, carcinoma in situ) or the submucosa (pT1) (1). Currently the most widespread treatment for the non-muscle-invasive bladder cancer is transurethral resection. Although this procedure is not morbidity free, there are few reports of potential complications (2).

In rare cases, extravesical metastasis has been reported, that’s because microperforation of bladder occurred after repeated transurethral resection of bladder tumor (TURBT) (3). In addition to this reason, increased internal pressure of the bladder greater than surrounding venous pressure after TURBT due to fluid infusion during procedure and high histologic grade of the tumor are associated with extravesical metastasis after TURBT (4, 5). Here we describe a case of extravesical metastasis occurring after repeated TURBT of non-invasive bladder cancer.

CASE REPORT

A 70-year-old man with no pre-existing diseases visited the hospital for gross hematuria. Contrast-enhanced spiral computed tomography (CT) images of the kidneys taken on admission showed an enhanced mass approximately 2 cm in size in the right posterior aspect of the bladder (Fig. 1A, B). Subsequent cystoscopy showed a mass on the right lateral wall of the bladder, and TURBT was performed. Pathological findings showed a low-grade by WHO, non-invasive papillary urothelial carcinoma (stage Tis), with only mucosal invasion. Eight years after first visit, contrast-enhanced CT showed a newly developed 2.7 cm sized polypoid mass in the lower anterior wall of the bladder.
Intraperitoneal Seeding after Transurethral Resection of Bladder Tumor

A. A contrast-enhanced CT image on early nephrographic phase shows an about 2.0 cm sized homogenous enhancing mass at right posterolateral wall of bladder (arrow).

B. A contrast-enhanced CT scan on excretory phase performed 8 years after first visit. An about 2.7 cm sized polyloid mass (arrow) is located in the lower anterior wall of bladder with no perivesical fatty infiltration nor abnormal lymphadenopathy.

C. Follow-up contrast-enhanced CT image on excretory phase, approximately four months after the final transurethral resection of bladder tumor. Ill-defined enhancing masses are developed in the perivesical space (arrows). This mass seemed to have invaded the bladder, seminal vesicle and adjacent peritoneum.

D. A coronal reconstructed CT image shows ill-defined, enhancing soft tissue lesion along the adjacent peritoneum (arrows).

E. Low power photomicrograph of the pathologic specimen obtained at extra-vesical mass around the bladder. Low power photomicrograph of the pathologic specimen obtained at extra-vesical mass around the bladder (arrow) shows low-grade infiltrating urothelial carcinoma (original magnification, × 200; hematoxylin-eosin stain).

CT = computed tomograph
bladder with no evidence of perivesical fatty infiltration or abnormal lymphadenopathy. Therefore he had second TURBT to remove this mass. Pathologic findings showed a low-grade by WHO, infiltrating urothelial carcinoma (stage T1), with only subepithelial connective tissue invasion. After that, TURBT was performed two times due to recurrence. Pathologic findings showed a low-grade, non-invasive papillary urothelial carcinoma, with no evidence of bladder perforation or extravesical metastasis. Approximately four months after the final TURBT, the patient presented to the hospital after being unable to urinate for approximately 2 days. Contrast-enhanced CT revealed a newly developed ill-defined soft tissue mass in the perivesical space. The mass seemed to have invaded the bladder, seminal vesicle, adjacent peritoneum, and right distal ureter, resulting in the development of right hydronephrosis (Fig. 1C, D). CT guided biopsy was performed on the patient's extravesical mass, and findings revealed metastatic, low-grade infiltrating urothelial carcinoma (Fig. 1E). Currently, the patient is receiving gemcitabine and carboplatin chemotherapy. He is undergoing follow-up, and has not shown any complications.

**DISCUSSION**

Bladder cancer accounts for 2% of all malignant neoplasms; it is the second most common urological cancer (2, 3). Cystoscopy and TURBT are the primary methods of diagnosis and treatment of bladder cancer, and they cause fewer complications and are less invasive compared to other treatment options. According to recent research findings, the overall complication rate of TURBT is 5–6%, with common complications including urinary tract infection, hemorrhage requiring transfusion, and bladder perforation. Extravesical metastasis and intraperitoneal seeding of tumor cells following TURBT are very rarely reported, respectively (2, 3, 6).

There are three mechanisms explaining distant metastasis after TURBT.

First, microperforation of bladder can cause peritoneal seeding. In rare cases, extravesical metastasis has been reported, that's because microperforation of bladder occurred after TURBT (3). Because TURBT is used to obtain a histologic diagnosis and to provide treatment through the resection of all visible disease, the scope of resection is usually deep and extensive, resulting in an increased risk of bladder perforation (7). In cases with heavily pretreated, thin-walled bladders; and when the size of the tumor is large and located posteriorly or in the bladder dome, there is a high risk of perforation (8). Although such bladder perforation is rare, care needs to be taken; because it can lead to peritoneal or abdominal wall metastasis (3). Mydlo et al. (3) reported a case in which extensive peritoneal metastasis and liver metastasis occurred due to intraperitoneal perforation 4 months following TURBT, while Bus et al. (9) also reported a case in which seeding occurred in both adnexa due to intraperitoneal perforation following TURBT. Repeated TURBT caused thinning of the bladder wall, which is thought to have increased the risk of microperforation. This is also thought to have caused seeding to the adjacent peritoneum. However there is no definite evidence of bladder perforation in our case on clinically and radiologically.

Second, increased internal pressure of the bladder after TURBT is the reason why the extravesical metastasis occurs (4). Engilbertson et al. (4) published a report on the seeding of cancer cells in the blood stream during TURBT. According to their study, the internal pressure of the bladder becomes greater than surrounding venous pressure due to fluid infusion during TURBT, which may lead to infusion of cancer cells into the surrounding venous system. A total of 16 patients took part in a test in which the number of cancer cells was measured in the inferior vena cava before and during TURBT. The results showed that the number of cancer cells increased significantly during TURBT. This study aimed to find an explanation for the occurrence of distant metastasis following TURBT, but they could not present actual data on the subject.

Third, it is generally accepted that tumor seeding or distant metastasis are associated with histologic grade of tumor (5). Papillary cancer of Ta grade 2 or 3 (high grade) tend to progress into the muscle-invasive bladder cancer and subsequent extravesical metastasis (10). However, the patient in our study initially had stage Tis bladder cancer with invasion only extending into the mucosal layer. He underwent TURBT treatment, but owing to subsequent recurrence, TURBT was conducted 4 additional times. During this procedure, the histologic grade of the tumor was not exceeding low-grade, infiltrating urothelial carcinoma (stage T1).

According to the 2011 European Association of Urology (EAU)
guidelines on non-muscle-invasive bladder cancer, patients need to be follow-up by radiologic modality including chest X-ray, cystoscopy and CT because of the risk of recurrence and progression; however, the frequency and duration of radiologic follow-up should reflect the degree of risk. Patients with small non-invasive (Ta), low-grade papillary tumors at low risk of recurrence and progression should have a cystoscopy at 3 month after TURBT. If negative, the following cystoscopy is advised 9 month later and then yearly for 5 years (1).

In summary, in patients who undergo TURBT to treat low-grade, Tis bladder cancer, and repeated TURBT due to recurrence during follow-up, thorough radiologic follow-up should be performed due to the risk of subsequent extravesical metastasis.

REFERENCES

비침습적 방광암의 경 요도 절제술 후 발생한 방광 외 전이에 대한 증례 보고

강가람1 · 손동완2 · 정동진3*

비침습적 방광암의 경 요도 절제술은 방광암의 첫 번째 치료 방법으로 알려져 있다. 비침습적 방광암의 경 요도 절제술의 흔한 합병증으로는 요로감염, 수혈이 필요한 정도의 출혈, 방광 천공 등이 있다. 반면 시술 후 종양의 방광 외 전이 및 복막으로의 파종 등은 매우 드물게 보고된다. 이에 저자들은 비침습적 방광암의 반복적인 경 요도 절제술 후 방광 외 전이가 발생한 증례를 보고하고자 한다.

1가톨릭대학교 의과대학 의정부성모병원 영상의학과, 가톨릭대학교 의과대학 여의도성모병원 2비뇨기과, 3영상의학과